Related Experiment Video
Updated: May 20, 2025
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Research hotspots and emerging trends in targeted therapy for colorectal cancer: a bibliometric analysis (2000-2023)
Xiangnv Meng1,2, Zhongting Lu1, Fu Mi2
1General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
Background:
Targeted therapy has significantly transformed the treatment landscape of colorectal cancer (CRC), enabling personalized treatment approaches and improving patient prognosis. This study employs bibliometric analysis to explore the research hotspots and development trends in the field of CRC-targeted therapy from 2000 to 2023.
Methods:
Based on the Web of Science Core Collection, this study collected literature related to CRC-targeted therapy published between 2000 and 2023. CiteSpace and VOSviewer were used for data analysis, with a focus on publication trends, key contributors, and keyword co-occurrence patterns.
Results:
A total of 2252 relevant articles were included, demonstrating a steady growth trend in research output. China ranked first in terms of the number of publications, while the University of Texas MD Anderson Cancer Center was identified as the institution with the highest research output. Josep Tabernero was the most prolific author in this field. Among journals, Cancers had the highest impact, while Clinical Cancer Research held a significant advantage in citation frequency. Keyword co-occurrence and clustering analysis indicated that research primarily focused on treatment strategies and precision medicine, with emerging technologies such as cell therapy and liquid biopsy garnering increasing attention.
Conclusion:
This study reveals the research trends, core hotspots, and emerging directions in the field of CRC-targeted therapy, providing valuable insights for future research.
Insights
Bibliometric analysis of colorectal cancer (CRC) targeted therapy reveals research trends and hotspots. Key areas include precision medicine, cell therapy, and liquid biopsy, offering insights for future advancements in CRC treatment.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Targeted therapy has revolutionized colorectal cancer (CRC) treatment, enabling personalized medicine and improved patient outcomes.
- Bibliometric analysis is utilized to map the research landscape of CRC-targeted therapy from 2000 to 2023.
Purpose of the Study:
- To identify research hotspots and development trends in colorectal cancer (CRC) targeted therapy.
- To analyze publication trends, key contributors, and keyword co-occurrence patterns in the field.
Main Methods:
- Bibliometric analysis of 2252 articles from the Web of Science Core Collection (2000-2023).
- Utilized CiteSpace and VOSviewer for data analysis, focusing on publication output, institutional contributions, author productivity, and journal impact.
- Examined keyword co-occurrence and clustering to identify thematic research areas.
Main Results:
- Research output shows a steady growth trend, with China leading in publications and the University of Texas MD Anderson Cancer Center as the top institution.
- Josep Tabernero is the most prolific author; Cancers and Clinical Cancer Research are leading journals in impact and citations, respectively.
- Primary research focus is on treatment strategies and precision medicine, with growing interest in cell therapy and liquid biopsy.
Conclusions:
- This bibliometric study provides a comprehensive overview of research trends, core hotspots, and emerging directions in CRC-targeted therapy.
- Findings offer valuable insights for researchers and clinicians aiming to advance the field of personalized colorectal cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
01:15Drugs that Stabilize Microtubules
01:21Cancer Survival Analysis